STAR
STAR Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
0 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
Strides aims to grow its U.S. Strides Pharma Science expects steady revenue growth driven by diversified businesses, particularly strong momentum in Ex-US markets. - Operational EBIT margin was maintained around 18.2% despite geopolitical and cost pressures. - Operational PAT grew 8% year-on-year with steady EBITDA-to-PAT conversion of 54%. - Reported PAT increased 56.7% due to a gain from divesting Pivot Path. - The company aims to maintain gross margins within 58-60% range. - Return on Capital Employed (ROCE) is expected to improve as recent investments mature. - Management focused on profitability and portfolio quality rather than growth at any cost for U.S.
From STAR's Q1 FY27 earnings-call transcript · updated 8 Sept 2026.
Revenue & Sales Performance
- Strides aims to grow its U.S. business from USD 285 million to USD 375 million by FY28, driven by five levers including OTC business, controlled substances, new product launches, specialty channels, and new partnerships.
- Controlled substances are expected to contribute significantly to growth following completion of past sales history demonstration (1.5 years demonstrated), with higher quota allocations anticipated from next cycles.
- Approximately 10 product launches are planned by March next year, focusing on higher-revenue potential products (USD 10-15 million each).
- Beyond FY28, growth is expected to be driven by advancements in three key domains—nasal sprays, transdermal patches, and thin films—with multiple filings and launches planned over next 12-18 months.
- Ex-U.S. markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA, and APAC.
- New approvals and improved supply chain activities are expected to strengthen momentum, especially in H2 of FY27.
Profitability & Margins
See what STAR said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current capex is a combination of maintenance capex, R&D, and hard capex, totaling about INR 2.5 to 3 billion per year.
- No greenfield capex is planned at this point; focus remains on enhancing existing factories and investing in high-impact line items.
- Strategic investment includes the sale of majority stake in Pivot Path, with retained 20% interest, expected to contribute to PAT in the next 4-5 years.
- The company continues investments in new technology platforms like nasal sprays, transdermal patches, films, and controlled substances to support future growth.
- Focus on portfolio quality, launching 10+ products in the next 6 months, with ongoing investments in product approvals and launches.
- Capex strategy supports operating leverage and sustained EPS and PAT growth over medium term, aligned with growth and profitability objectives.
Fundraising & Capital Structure
See what STAR said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
STAR — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.3K Cr, net profit ₹129 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Strides Pharma Science Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were STAR Q1 FY27 results?
Strides aims to grow its U.S. Strides Pharma Science expects steady revenue growth driven by diversified businesses, particularly strong momentum in Ex-US markets. - Operational EBIT margin was maintained around 18.2% despite geopolitical and cost pressures. - Operational PAT grew 8% year-on-year with steady EBITDA-to-PAT conversion of 54%. - Reported PAT increased 56.7% due to a gain from divesting Pivot Path. - The company aims to maintain gross margins within 58-60% range. - Return on Capital Employed (ROCE) is expected to improve as recent investments mature. - Management focused on profitability and portfolio quality rather than growth at any cost for U.S.
What is STAR share price analysis?
STAR currently shows a below-average growth signal. The stock trades at a P/E of 16.9 with a market cap of ₹9,767 Cr. Investors should review the full earnings analysis for detailed insights.
Is STAR planning capital expenditure?
Current capex is a combination of maintenance capex, R&D, and hard capex, totaling about INR 2.5 to 3 billion per year.
Keep STAR on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.